ATG-112 / Antengene - LARVOL DELTA

ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G+ solid tumors (AACR 2026) - "It demonstrates potent in vitro and in vivo efficacy with minimal cytokine release. These findings support ATG-112 as a differentiated and promising therapeutic candidate for ALPP/G-positive solid tumors and justify its advancement toward clinical development."

Bispecific • IO biomarker • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • ALPP

Business Updates: AnTenGager TCE Platform (PRNewswire) - "The Company plans to submit an IND application for ATG-106 in the second quarter of 2027.... The Company plans to submit an IND application for ATG-112 in the second quarter of 2027....Antengene plans to submit an IND application for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer."

IND • Bladder Cancer • Colorectal Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma

Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G+ solid tumors (PRNewswire) - "Antengene to Present on...Preclinical Programs at AACR 2026....ATG-112 demonstrated high binding affinity to ALPP/G-positive tumor cells and induced potent antigen-dependent T cell-mediated cytotoxicity in vitro. In PBMC humanized xenograft tumor models, ATG-112 showed dose-dependent tumor growth inhibition and robust antitumor activity."

Preclinical • Solid Tumor

ATG-112 (ALPPL2 x CD3 TCE) (PRNewswire) - "A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026."

Pipeline update • Gynecologic Cancers • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma